Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Search Seller Projects – Healthcare

Page of 4
Asia - North Asia & China: Korea

Korean cancer treatment company seeks investment

The Korean cancer treatment company has a bioelectronic nose sensor which can detect cancer earlier than other sensors or instruments on the market. The examinee only needs to exhale on the inspection machine for about 1 minute to complete the inspection, and there is no discomfort during the inspection process. At present, the company has cooperated with Seoul National University Cancer Hospital, Renji Hospital, Korea Institute of science and Technology (KIST), etc. The company seeks investment now.
Asia - North Asia & China: Korea

Korean AI medical diagnosis firm seeks USD 2.5 million investment

The Korean AI medical company's products include a cervical cancer diagnosis AI system, an early AI diagnosis for stroke risk, a stroke risk prediction AI system based ob carotid ultrasound images, and a cerebral aneurysm rupture risk prediction AI system based on cerebral angiography images. The company has developed a international system with various languages to ensure that all medical personnel around the world can use its AI diagnosis solutions. Its partners include Swedish medical device manufacturer Gynius plus AB and Canadian health care company Variational AI. The company seeks USD 2.5 million for equity financing.
Middle East: Israel

Israeli medical equipment company seeks strategic partners and investment.

The Israeli medical equipment company has several innovative products. These products include drug delivery catheters (any drug, specific dose, platform technology), Vascular transplantation equipment, and special needles. The company seeks strategic partners and investment.
Middle East: Israel

Israeli company focuses on Ophthalmology seeks investment.

The Israeli company focuses on Ophthalmology and has a project which on a diagnostic solution that can provide multi-parameter, objective, rapid, simple, and semi quantitative tear film analysis to identify one or more potential causes. The project may not only become a clinically valuable real-time test, but also an auxiliary diagnostic test to meet the needs of rapid diagnosis and personalized medical treatment. The project is a cost-effective, easy-to-use, and objective solution that will enable eye care professionals to diagnose and treat patients, including patients who may not be diagnosed or whose condition remain uncertain. The company has completed three clinical trials in the United States and plans to carry out key trials with FDA. Now, the company seeks investment.
Middle East: Israel

Israeli medical company seeks investment for its Ophthalmic project.

The Israeli medical company is a joint venture, which authorizes the use of non-invasive local drug delivery technology, which is used to treat posterior ocular diseases by eye drops instead of current drug delivery methods (such as intravitreal injection). The platform technology can also be used for eye treatment. The project is currently in the preclinical stage of the development of a few candidate products. The company seeks investment for this project.
Middle East: Israel

Israeli cancer treatment center seeks investment.

The Israeli cancer treatment center has a project which specializes in the development and commercialization of innovative in vitro cancer diagnostic products and solutions. The product portfolio includes the latest technologies involving gene expression, biomarkers, and histochemical analysis for early cancer detection and personalized medicine. The project provides proprietary diagnostic solutions for a variety of cancer diagnostic applications and practical answers to unmet practical needs. The center seeks investment.
Middle East: Israel

Israeli medical company seeks investment.

The Israeli medical company has a product that is a microemulsion composed of phospholipids and triglycerides. It can form a tear film like elastic lipid shield to improve vision. It is a CE-certified III drug. Project is designated for post-operative ophthalmic surgery (e.g., refractive surgery, cataract surgery, and corneal transplantation), corneal erosion, and dry eye syndrome. This product is the only product on the eye drops market with clinical evidence that corneal epithelium thickens again after mechanical, traumatic, and surgical epithelial loss. As a microemulsion carrier, the technology can be used as a drug delivery platform in the pre-clinical stage. Its unique pharmaceutical advantages include a longer contact time between drug and eye surface which can increase compliance. The company seeks investment.
Middle East: Israel

Israeli medical equipment company seeks investment.

The Israeli medical equipment company has a solution for outpatient ophthalmology departments, which can control the release of ophthalmic drugs over time, so as to solve the problem of inaccurate eye drop dispensing, enabling patients to 100% comply with the drug treatment plan. The device can be applied to the most prescribed glaucoma drugs. The product has completed a clinical study under the regulatory pathway procedure of FDA 505 (b) (2) as part of the application of new drugs. The goal of the company is to further develop the platform to treat other eye diseases. At present, the company seeks investment for its next step.
Middle East: Israel

Israeli medical equipment company seeks investment.

The Israeli medical equipment company created a pulmonary edema monitor (non-invasive) device. Pulmonary effusion is the main cause of decompensation and hospitalization of heart failure. The determination of pulmonary effusion in the first stage is crucial. Otherwise, the treatment effect is poor. Since the lung is a chest organ, it is difficult to measure the amount of pulmonary effusion in the first stage. The new device based on the new patented technology can distinguish the fluid of the whole chest from the fluid of the lungs. Compared with the existing device, this method improves the sensitivity of measuring lung fluid by 25 times. The device has high predictive sensitivity for hospitalization of heart failure (98%), can determine very small changes in lung fluid and start preventive treatment early in the decompensation of heart failure. Some studies using the device have found that the use of the device in the hospital can greatly shorten the length of hospital stay and improve the mortality in the hospital and after discharge. Home care using the device showed a 65% reduction in the number of hospitalizations and a 60% reduction in mortality. At present, the company seeks investment.
Middle East: Israel

Israeli medical company seeks investment.

The respiratory medical company in Israel has developed a medical device for the treatment of COPD (chronic obstructive pulmonary disease). The mission is to alleviate the suffering of critically ill patients with COPD. The device is a non-invasive pressure pulse generator. Its unique pressure wave and frequency make it a super unique and effective method to open the airway of pulmonary collapse in COPD. At present, the company seeks investment.
Middle East: Israel

Israeli medical company seeks market expansion.

The Israeli company holds 24 patents with new and innovative medical devices. The company has been approved by FDA and CE. The company develops and targets minimally invasive cryoablation therapy for women's health and interventional oncology (kidney cancer, lung cancer, liver cancer, bone cancer, and prostate cancer). The system provides outpatient definitive treatment for breast tumors and ablation of other cancerous tumors in the body. Clinical trials have been completed in Europe, America, and Japan. In Europe, Latin America, Asia, and other markets, initial sales are around USD 500 million. The company also targets breast cancer markets. The goal of the company is to seek investment for market expansion.
Middle East: Israel

Isreali cancer treatment company seeks investment

The Israeli cancer treatment company is developing a new biological / drug platform (NADAV technology) - a proprietary strain based on oncolytic virus NDV, which can target a variety of cancers. A series of in vivo, in vitro and clinical studies on NDV strains, show that NDV strains retain the potential selective and targeted cell death (apoptosis) mechanism of human cancer cells. Another virus named Mucus virus can preferentially replicate and kill cancer cells. For the virus to have oncolytic effect, it must be safe for human beings, only kill cancer cells while retaining normal cells, and genetic stability. The company seeks investment.

Filter

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive